AR028817A1 - Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen - Google Patents
Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienenInfo
- Publication number
- AR028817A1 AR028817A1 ARP000101297A ARP000101297A AR028817A1 AR 028817 A1 AR028817 A1 AR 028817A1 AR P000101297 A ARP000101297 A AR P000101297A AR P000101297 A ARP000101297 A AR P000101297A AR 028817 A1 AR028817 A1 AR 028817A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- pyrrolidine
- phenyl
- compounds derived
- arenosulfonil
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- OOVSRCPGHGCJAM-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-2-phenylpyrrolidine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C=2C=CC=CC=2)CCC1 OOVSRCPGHGCJAM-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Compuestos derivados de la 1 -arenosulfonil- 2 - arilo- pirrolidina de formula general 1 en donde R1 significa, hidrogeno, alquilo inferior o hidroxilo --alquilo inferior; R2 significa furilo, tienilo, piridilo o fenilo, el cual está opcionalmente sustituido por 1 a 3 sustituyentes seleccionado de alquilo inferior, alcoxilo inferior, halogeno, ciano, CF3 o -N (R4)2; R3 significa naftilo o fenilo, el cual está opcionalmente sustituido con 1 a 3 sustituyentes de alquilo inferior, alcoxilo inferior, halogeno, acetilo, ciano, hidroxilo - -alquilo inferior, -CH2 - morfolin- 4- ilo, alquilo inferior- oxi- alquilo inferior, alquilo inferior - N(R4)2 o CF3; R4 significa, independientemente entre sí, hidrogeno o alquilo inferior, con la excepcion de la (RS) - 2 - fenil - 1 - (toluen - 4 -sulfonil)- pirrolidina y (RS) - 1- (toluen- 4 - sulfonil)- 2 - ptolil- pirrolidina así como sus sales farmacéuticamente aceptables. Los compuestos descritos más arriba son antagonistas o agonistas del receptor metabotropico de glutamato, y por lo tanto son de utilidad en el tratamiento de los correspondientes trastornos del SNC.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99106004 | 1999-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR028817A1 true AR028817A1 (es) | 2003-05-28 |
Family
ID=8237852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000101297A AR028817A1 (es) | 1999-03-25 | 2000-03-23 | Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6284785B1 (es) |
| EP (1) | EP1165510B1 (es) |
| JP (1) | JP3590589B2 (es) |
| KR (1) | KR100452648B1 (es) |
| CN (1) | CN1150165C (es) |
| AR (1) | AR028817A1 (es) |
| AT (1) | ATE305451T1 (es) |
| AU (1) | AU765212B2 (es) |
| BR (1) | BR0009278A (es) |
| CA (1) | CA2368418C (es) |
| CO (1) | CO5050296A1 (es) |
| CZ (1) | CZ20013402A3 (es) |
| DE (1) | DE60022867T2 (es) |
| DK (1) | DK1165510T3 (es) |
| ES (1) | ES2249249T3 (es) |
| HK (1) | HK1044944B (es) |
| HR (1) | HRP20010682A2 (es) |
| HU (1) | HUP0200284A3 (es) |
| IL (1) | IL145301A0 (es) |
| JO (1) | JO2274B1 (es) |
| MA (1) | MA26779A1 (es) |
| MX (1) | MXPA01009623A (es) |
| MY (1) | MY125295A (es) |
| NO (1) | NO319948B1 (es) |
| NZ (1) | NZ514037A (es) |
| PE (1) | PE20001583A1 (es) |
| PL (1) | PL204436B1 (es) |
| RU (1) | RU2248350C2 (es) |
| SI (1) | SI1165510T1 (es) |
| TR (1) | TR200102789T2 (es) |
| TW (1) | TW575561B (es) |
| WO (1) | WO2000058285A1 (es) |
| YU (1) | YU67601A (es) |
| ZA (1) | ZA200107689B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010052503A (ko) | 1998-06-03 | 2001-06-25 | 다니엘 피. 맥컬럼 | Ｎ-헤테로사이클릭 카복실산 또는 카복실산 등입체의ｎ-결합된 설폰아미드 |
| US6589978B2 (en) | 2000-06-30 | 2003-07-08 | Hoffman-La Roche Inc. | 1-sulfonyl pyrrolidine derivatives |
| US20040267010A1 (en) * | 2001-02-02 | 2004-12-30 | Forbes Ian Thomson | Sulfonamide compounds, their preparation and use |
| TW200302717A (en) * | 2002-02-06 | 2003-08-16 | Schering Corp | Novel gamma secretase inhibitors |
| EP1667983A4 (en) * | 2003-09-23 | 2010-07-21 | Merck Sharp & Dohme | PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
| WO2005079795A2 (en) * | 2004-02-20 | 2005-09-01 | Novartis Ag | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
| EP1758884A2 (en) * | 2004-05-20 | 2007-03-07 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| EP1803709B1 (en) | 2004-09-30 | 2013-01-02 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| ATE504567T1 (de) | 2005-08-30 | 2011-04-15 | Takeda Pharmaceutical | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl-substitutierte 1-h-pyrrolderivate als säuresekretionshemmer |
| AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| JP2009536667A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | ５ｈｔ受容体介在性の神経新生 |
| MX2009002496A (es) | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US8933105B2 (en) | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| ES2423289T3 (es) | 2008-08-27 | 2013-09-19 | Takeda Pharmaceutical Company Limited | Compuestos de pirrol |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| US10603313B2 (en) | 2017-07-31 | 2020-03-31 | Chiromics, LLC | Allosteric modulators of the mu opioid receptor |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK167393B1 (da) * | 1985-12-30 | 1993-10-25 | Roussel Uclaf | 1-sulfonyl-2-oxo-pyrrolidinderivater, deres fremstilling og farmaceutiske praeparater med indhold deraf |
| US5194439A (en) * | 1990-04-06 | 1993-03-16 | John Wyeth & Brother Limited | N-(2,3-dihydro-1,4-benzodioxinyl)-N-substituted aminopyrido-fused cycloalkanes |
| DE69205287T2 (de) * | 1991-12-18 | 1996-03-14 | Schering Corp., Kenilworth, N.J. | Imidazolylalkyl- piperazin und -diazepin derivate als histamin h3 agonisten/antagonisten. |
| FR2685325B1 (fr) * | 1991-12-20 | 1994-02-04 | Adir Cie | Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9612884D0 (en) * | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
-
2000
- 2000-03-13 TW TW89104504A patent/TW575561B/zh active
- 2000-03-18 PL PL350679A patent/PL204436B1/pl not_active IP Right Cessation
- 2000-03-18 EP EP00910863A patent/EP1165510B1/en not_active Expired - Lifetime
- 2000-03-18 IL IL14530100A patent/IL145301A0/xx unknown
- 2000-03-18 HK HK02106320.6A patent/HK1044944B/zh not_active IP Right Cessation
- 2000-03-18 CA CA002368418A patent/CA2368418C/en not_active Expired - Fee Related
- 2000-03-18 CZ CZ20013402A patent/CZ20013402A3/cs unknown
- 2000-03-18 DK DK00910863T patent/DK1165510T3/da active
- 2000-03-18 RU RU2001126570/04A patent/RU2248350C2/ru not_active IP Right Cessation
- 2000-03-18 HU HU0200284A patent/HUP0200284A3/hu unknown
- 2000-03-18 CN CNB008055300A patent/CN1150165C/zh not_active Expired - Fee Related
- 2000-03-18 SI SI200030753T patent/SI1165510T1/sl unknown
- 2000-03-18 KR KR10-2001-7012227A patent/KR100452648B1/ko not_active Expired - Fee Related
- 2000-03-18 AT AT00910863T patent/ATE305451T1/de active
- 2000-03-18 MX MXPA01009623A patent/MXPA01009623A/es active IP Right Grant
- 2000-03-18 HR HR20010682A patent/HRP20010682A2/hr not_active Application Discontinuation
- 2000-03-18 JP JP2000607988A patent/JP3590589B2/ja not_active Expired - Fee Related
- 2000-03-18 TR TR2001/02789T patent/TR200102789T2/xx unknown
- 2000-03-18 BR BR0009278-9A patent/BR0009278A/pt active Search and Examination
- 2000-03-18 DE DE60022867T patent/DE60022867T2/de not_active Expired - Lifetime
- 2000-03-18 ES ES00910863T patent/ES2249249T3/es not_active Expired - Lifetime
- 2000-03-18 AU AU32915/00A patent/AU765212B2/en not_active Ceased
- 2000-03-18 WO PCT/EP2000/002431 patent/WO2000058285A1/en not_active Ceased
- 2000-03-18 YU YU67601A patent/YU67601A/sh unknown
- 2000-03-20 PE PE2000000241A patent/PE20001583A1/es not_active Application Discontinuation
- 2000-03-22 CO CO00020380A patent/CO5050296A1/es unknown
- 2000-03-23 JO JO200025A patent/JO2274B1/en active
- 2000-03-23 MY MYPI20001145A patent/MY125295A/en unknown
- 2000-03-23 AR ARP000101297A patent/AR028817A1/es unknown
- 2000-03-24 US US09/534,380 patent/US6284785B1/en not_active Expired - Fee Related
-
2001
- 2001-09-18 ZA ZA200107689A patent/ZA200107689B/xx unknown
- 2001-09-24 NO NO20014617A patent/NO319948B1/no unknown
- 2001-09-25 MA MA26339A patent/MA26779A1/fr unknown
-
2004
- 2004-01-30 NZ NZ514037A patent/NZ514037A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR028817A1 (es) | Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen | |
| NO20050429L (no) | Substituert kinolin-CCR5-reseptorantagonister | |
| NO20032253L (no) | Piperazinylpyrazinforbindelser som antagonister av serotonin 5-HT2-reseptorer | |
| NO20051260L (no) | Arylsubstituerte diazabicykloalkaner som nikotinacetylcholinagonister | |
| NO20052737D0 (no) | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them. | |
| ATE377589T1 (de) | 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten | |
| DK1539742T3 (da) | Indolderivater, der er nyttige som histamin H3-antagonister | |
| ATE496620T1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| ATE203990T1 (de) | Indolderivat als 5-ht1a antagonist und als inhibitor der serotonin-wiederaufnahme | |
| IS7923A (is) | 2-oxó-1-pýrrólidín afleiða og lyfjafræðileg notkun hennar | |
| EA200301073A1 (ru) | N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора | |
| AR008829A1 (es) | Derivados 6,6- o 6,7 biciclicos sustituidos que contienen pirido o pirimido como agentes antagonistas para el tratamiento de enfermedades gastrointestinales, inflamatorias y del snc, y composicion farmaceutica | |
| DE69819173D1 (de) | Indole und 2,3-dihydroindolderivate, ihre herstellung und verwendung | |
| NO20041504L (no) | Lactamderivater som antagonister for humane 11CBY reseptorer. | |
| PE20040935A1 (es) | Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina | |
| ES2142818T3 (es) | Composicion farmaceutica a base de cyclosporin. | |
| EA199700156A1 (ru) | Производные индола как антагонисты рецептора 5-нт | |
| ES2113368T3 (es) | Antagonistas de serotonina. | |
| TR200101155T2 (tr) | 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III | |
| ATE399770T1 (de) | Tachykininrezeptorantagonisten | |
| AR009413A1 (es) | Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende | |
| AR035153A1 (es) | Derivados de carboxamidas y cetonas de dihidrobenzodioxina | |
| PE20040698A1 (es) | Derivados de isoindolina | |
| NO20080165L (no) | Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister | |
| EA200500830A1 (ru) | Производные имидазохинолина в качестве лигандов аденозиновых a3 рецепторов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |